Fig. 2.

Comparison of stimulatory capacity from cDC1, and serum levels of TGF-β1 between controls and pancreatic cancer patients before operation. a The stimulatory capacity of cDC1 in patients with pancreatic cancer was significantly lower than that of controls (P=0.005). b Serum TGF-β1 levels of pancreatic cancer patients were significantly higher than controls (P<0.001). The data are expressed as the median (interquartile interval). Statistical significance was determined using the Mann–Whitney U test